First Time Loading...

Kodiak Sciences Inc
NASDAQ:KOD

Watchlist Manager
Kodiak Sciences Inc Logo
Kodiak Sciences Inc
NASDAQ:KOD
Watchlist
Price: 3.38 USD 1.5% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

KOD's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. [ Read More ]

The intrinsic value of one KOD stock under the Base Case scenario is 1.78 USD. Compared to the current market price of 3.38 USD, Kodiak Sciences Inc is Overvalued by 47%.

Key Points:
KOD Intrinsic Value
Base Case
1.78 USD
Overvaluation 47%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Kodiak Sciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling KOD stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Kodiak Sciences Inc

Provide an overview of the primary business activities
of Kodiak Sciences Inc.

What unique competitive advantages
does Kodiak Sciences Inc hold over its rivals?

What risks and challenges
does Kodiak Sciences Inc face in the near future?

Has there been any significant insider trading activity
in Kodiak Sciences Inc recently?

Summarize the latest earnings call
of Kodiak Sciences Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Kodiak Sciences Inc.

Provide P/S
for Kodiak Sciences Inc.

Provide P/E
for Kodiak Sciences Inc.

Provide P/OCF
for Kodiak Sciences Inc.

Provide P/FCFE
for Kodiak Sciences Inc.

Provide P/B
for Kodiak Sciences Inc.

Provide EV/S
for Kodiak Sciences Inc.

Provide EV/GP
for Kodiak Sciences Inc.

Provide EV/EBITDA
for Kodiak Sciences Inc.

Provide EV/EBIT
for Kodiak Sciences Inc.

Provide EV/OCF
for Kodiak Sciences Inc.

Provide EV/FCFF
for Kodiak Sciences Inc.

Provide EV/IC
for Kodiak Sciences Inc.

Show me price targets
for Kodiak Sciences Inc made by professional analysts.

What are the Revenue projections
for Kodiak Sciences Inc?

How accurate were the past Revenue estimates
for Kodiak Sciences Inc?

What are the Net Income projections
for Kodiak Sciences Inc?

How accurate were the past Net Income estimates
for Kodiak Sciences Inc?

What are the EPS projections
for Kodiak Sciences Inc?

How accurate were the past EPS estimates
for Kodiak Sciences Inc?

What are the EBIT projections
for Kodiak Sciences Inc?

How accurate were the past EBIT estimates
for Kodiak Sciences Inc?

Compare the revenue forecasts
for Kodiak Sciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Kodiak Sciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Kodiak Sciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Kodiak Sciences Inc compared to its peers.

Compare the P/E ratios
of Kodiak Sciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Kodiak Sciences Inc with its peers.

Analyze the financial leverage
of Kodiak Sciences Inc compared to its main competitors.

Show all profitability ratios
for Kodiak Sciences Inc.

Provide ROE
for Kodiak Sciences Inc.

Provide ROA
for Kodiak Sciences Inc.

Provide ROIC
for Kodiak Sciences Inc.

Provide ROCE
for Kodiak Sciences Inc.

Provide Gross Margin
for Kodiak Sciences Inc.

Provide Operating Margin
for Kodiak Sciences Inc.

Provide Net Margin
for Kodiak Sciences Inc.

Provide FCF Margin
for Kodiak Sciences Inc.

Show all solvency ratios
for Kodiak Sciences Inc.

Provide D/E Ratio
for Kodiak Sciences Inc.

Provide D/A Ratio
for Kodiak Sciences Inc.

Provide Interest Coverage Ratio
for Kodiak Sciences Inc.

Provide Altman Z-Score Ratio
for Kodiak Sciences Inc.

Provide Quick Ratio
for Kodiak Sciences Inc.

Provide Current Ratio
for Kodiak Sciences Inc.

Provide Cash Ratio
for Kodiak Sciences Inc.

What is the historical Revenue growth
over the last 5 years for Kodiak Sciences Inc?

What is the historical Net Income growth
over the last 5 years for Kodiak Sciences Inc?

What is the current Free Cash Flow
of Kodiak Sciences Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Kodiak Sciences Inc.

Financials

Balance Sheet Decomposition
Kodiak Sciences Inc

Current Assets 289.3m
Cash & Short-Term Investments 285.5m
Other Current Assets 3.8m
Non-Current Assets 190.1m
PP&E 175m
Other Non-Current Assets 15m
Current Liabilities 41.7m
Accounts Payable 13.6m
Accrued Liabilities 28.1m
Non-Current Liabilities 171.9m
Other Non-Current Liabilities 171.9m
Efficiency

Earnings Waterfall
Kodiak Sciences Inc

Revenue
0 USD
Operating Expenses
-277.3m USD
Operating Income
-277.3m USD
Other Expenses
16.8m USD
Net Income
-260.5m USD

Free Cash Flow Analysis
Kodiak Sciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

KOD Profitability Score
Profitability Due Diligence

Kodiak Sciences Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Kodiak Sciences Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

KOD Solvency Score
Solvency Due Diligence

Kodiak Sciences Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
45/100
Solvency
Score

Kodiak Sciences Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

KOD Price Targets Summary
Kodiak Sciences Inc

Wall Street analysts forecast KOD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KOD is 4.34 USD with a low forecast of 2.02 USD and a high forecast of 7.35 USD.

Lowest
Price Target
2.02 USD
40% Downside
Average
Price Target
4.34 USD
28% Upside
Highest
Price Target
7.35 USD
117% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

KOD Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

KOD Price
Kodiak Sciences Inc

1M 1M
-45%
6M 6M
+141%
1Y 1Y
-27%
3Y 3Y
-97%
5Y 5Y
-54%
10Y 10Y
-67%
Annual Price Range
3.38
52w Low
1.4
52w High
9.48
Price Metrics
Average Annual Return 200.71%
Standard Deviation of Annual Returns 425.4%
Max Drawdown -99%
Shares Statistics
Market Capitalization 177.5m USD
Shares Outstanding 52 508 600
Percentage of Shares Shorted 6.33%

KOD Return Decomposition
Main factors of price return

What is price return decomposition?

KOD News

Last Important Events
Kodiak Sciences Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Kodiak Sciences Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Kodiak Sciences Inc Logo
Kodiak Sciences Inc

Country

United States of America

Industry

Biotechnology

Market Cap

177.5m USD

Dividend Yield

0%

Description

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Palo Alto, California and currently employs 93 full-time employees. The company went IPO on 2018-10-04. The Company’s Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. The Company’s lead product candidate includes KSI-301, which is an antibody biopolymer conjugate being investigated in multiple pivotal studies in retinal vascular diseases, including wAMD, DME, RVO and non-proliferative diabetic retinopathy. KSI-301 is under Phase IIb/III clinical trials. The Company’s other pipeline candidates includes product candidates KSI-501 and KSI-601, which are developed for the treatment of other unmet needs in retina, such as dry AMD and glaucoma. The Company’s subsidiary includes Kodiak Sciences GmbH.

Contact

CALIFORNIA
Palo Alto
1200 Page Mill Rd
+16502810850.0
https://kodiak.com/

IPO

2018-10-04

Employees

93

Officers

Co-Founder, Chairman, CEO & President
Dr. Victor Perlroth M.D.
Senior VP, CFO & Secretary
Mr. John A. Borgeson CPA, M.B.A.
Senior VP of Digital Transformation & Chief Information Officer
Dr. Michael S. Louie Ph.D.
Senior Vice President of Discovery Medicine
Dr. Hong Liang
Senior Vice President of Chemical Development & Manufacturing
Dr. Stephen Raillard Ph.D.
Senior Vice President of Quality Operations
Ms. Almas Qudrat M.Sc.
Show More
Senior VP of Clinical Research & Development
Dr. J. Pablo Velazquez-Martin M.D.
VP & Corporate Controller
Tracy Chien
Show Less

See Also

Discover More
What is the Intrinsic Value of one KOD stock?

The intrinsic value of one KOD stock under the Base Case scenario is 1.78 USD.

Is KOD stock undervalued or overvalued?

Compared to the current market price of 3.38 USD, Kodiak Sciences Inc is Overvalued by 47%.